RELATIONSHIP BETWEEN SOME CLINICAL AND PARACLINICAL FEATURES AND GLOMERULONOSCLEROSIS IN IGA NEPHROPATHY

Thị Như Cao, Gia Tuyển Đỗ, Thùy Dương Nguyễn, Trung Dũng Nghiêm

Main Article Content

Abstract

Objective: Describe clinical and paraclinical characteristics and compare glomerulosclerosis lesions in 80 patients with IgA nephropathy. Subjects and methods: cross-sectional, prospective study on 80 patients with IgAN from September 2023 to January 2025. Results: The most common clinical symptoms were microscopic hematuria (75%) and hypertension (27.5%). The time from diagnosis to renal biopsy was 12.42 ± 25.67 months. The most common immune deposits were IgA in the mesangium (100%) and C3 in the mesangium (88.7%). The most common histopathological features were mesangial cell proliferation (27.5%) and focal glomerulosclerosis (57.5%). The rate of glomerulosclerosis was higher in the group of patients with hypertension and proteinuria ≥ 1g/day. The more mesangial C3 deposition, the more glomerulosclerotic lesions increased, the difference was statistically significant (p < 0.05). Conclusion: IgA nephropathy progresses silently for many years with symptoms of microscopic hematuria, but leads to glomerulosclerosis and renal function decline over time.

Article Details

References

Gleeson PJ, O’Shaughnessy MM, Barratt J. IgA nephropathy in adults—treatment standard. Nephrol Dial Transplant. 2023;38(11):2464-2473. doi:10.1093/ndt/gfad146
2. Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: An interesting autoimmune kidney disease. Am J Med Sci. 2021;361(2):176-194. doi:10.1016/j.amjms.2020.10.003
3. Pattrapornpisut P, Avila-Casado C, Reich HN. IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021;78(3):429-441. doi:10.1053/ j.ajkd.2021.01.024
4. Gaumond L, Lamarche C, Beauchemin S, et al. Identification of inflammatory biomarkers in IgA nephropathy using the NanoString technology: a validation study in Caucasians. Inflamm Res. 2024;73(3):447-457. doi:10.1007/ s00011-023-01848-3
5. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100(4): S1-S276. doi:10.1016/j.kint.2021. 05.021
6. Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5): 1014-1021. doi:10.1016/j.kint.2017. 02.003
7. Najafian B, Lusco MA, Alpers CE, Fogo AB. Approach to Kidney Biopsy: Core Curriculum 2022. Am J Kidney Dis. 2022;80(1):119-131. doi:10.1053/j.ajkd.2021.08.024
8. Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol CJASN. 2017;12(4):677-686. doi:10.2215/CJN.07420716